Lisata Therapeutics, Inc.

Report topline data from Phase 2b trial of MAR001/005 in severe hypertriglyceridemia

Deadline not yet reached (430 days left)

Announced: 17 Sep 2026
Due: 31 Dec 2027

Deadline
Met
Late
Not met
Today

What the company said

“Both studies are expected to report topline data in the fourth quarter of 2027.”

SourceLisata Therapeutics, Inc. Form 8-K press release, 2026-09-17
FilingSEC filing index
Deadline as statedthe fourth quarter of 2027
Deadline used31 Dec 2027, the last day of the stated period
TypeProduct
Permanent referenceKI-C-2026-LSTA-000785
Cite as https://keptindex.org/c/KI-C-2026-LSTA-000785/ — this address never changes.

What we found

The deadline has not passed yet, so there is nothing to check. We look for evidence starting 30 days after 31 Dec 2027.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical readout
Indicative materiality: Medium rules
Action: Report
Language: Expected (“expects”, “plans”)

Tell me what happens

This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.

Alert me when this resolves

How this entry was checked

Commitment recordedRecorded from the company's filing.
OutcomeNot yet assessed. Nothing is judged before the deadline.

Are you Lisata Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2026-LSTA-000785 · Corrections policy